Sonnet BioTherapeutics (SONN)
(Delayed Data from NSDQ)
$5.15 USD
-0.01 (-0.10%)
Updated Oct 4, 2024 03:40 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SONN 5.15 -0.01(-0.10%)
Will SONN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for SONN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SONN
Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study
Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More
SONN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Beat the Market the Zacks Way: Vertiv, Costco, Sonnet BioTherapeutics in Focus
Other News for SONN
Sonnet BioTherapeutics receives funding through NJEDA, Australia tax programs
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
Sonnet BioTherapeutics announces launch of CEO Corner platform
Sonnet Biotherapeutics Holdings Inc trading halted, news pending
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split